Pheochromocytomas and Paragangliomas Market Expected to Grow at a CAGR of 8.60% Through 2034, DelveInsight Finds

The Pheochromocytomas and Paragangliomas (PCPG) market was valued at approximately USD 314 million in 2025 and is projected to grow at a CAGR of 8.60% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into the Pheochromocytomas and Paragangliomas market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Pheochromocytomas and Paragangliomas landscape. By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Pheochromocytomas and Paragangliomas market is being driven by the recent approval of WELIREG (belzutifan) by the FDA in May 2025, which represents the first oral systemic therapy for locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma. This HIF-2α inhibitor approval marks a significant advancement in the treatment landscape for patients aged 12 years and older.

DelveInsight's report, "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast- 2034," provides a comprehensive analysis of the Pheochromocytomas and Paragangliomas landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Pheochromocytomas and Paragangliomas market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Pheochromocytomas and Paragangliomas market outlook, drug uptake, treatment scenario and epidemiology trends, visit Pheochromocytomas and Paragangliomas Market Forecast

Some of the key facts of the Pheochromocytomas and Paragangliomas Market Report:

• Key Pheochromocytomas and Paragangliomas Companies: Merck, Jazz Pharmaceuticals/Chimerix, Perspective Therapeutics, Novartis, and others.
• Key Pheochromocytomas and Paragangliomas Therapies: WELIREG (belzutifan), ONC201, [212Pb]VMT-α-NET, LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), and others.
• The Pheochromocytomas and Paragangliomas market is expected to surge due to the disease's increasing awareness and improved detection rates during the forecast period. Furthermore, launching various pipeline Pheochromocytoma and Paragangliomas therapies and the recent FDA approval of WELIREG will significantly revolutionize the Pheochromocytoma and Paragangliomas market dynamics.

Pheochromocytomas and Paragangliomas Overview

Pheochromocytomas and paragangliomas are rare neuroendocrine tumors originating from chromaffin cells. Pheochromocytomas arise from the adrenal medulla, while paragangliomas develop from extra-adrenal sympathetic and parasympathetic ganglia. These tumors can produce excessive catecholamines, leading to symptoms such as hypertension, palpitations, headaches, and sweating. Pheochromocytomas and Paragangliomas have a strong hereditary component, with approximately 40% of cases involving germline mutations in susceptibility genes. Surgical resection remains the primary treatment for localized disease, while advanced or metastatic cases require systemic therapies. Accurate diagnosis through biochemical testing and genetic screening is essential for appropriate management.

Key Trends in Pheochromocytomas and Paragangliomas Therapeutics Market:

• First FDA-Approved Oral Therapy: WELIREG (belzutifan) approval in May 2025 as the first oral systemic therapy for advanced Pheochromocytomas and Paragangliomas
• Radioligand Therapy Innovation: Development of targeted radionuclide therapies including PRRT with SSTR2 agonists and alpha-emitting agents
• Precision Medicine Approaches: Enhanced genetic testing and biomarker-driven treatment strategies based on germline mutations
• Pipeline Advancement: Multiple investigational therapies in clinical trials, including ONC201 and [212Pb]VMT-α-NET
• Combination Therapy Research: Exploration of targeted molecular therapies combined with traditional approaches

Pheochromocytomas and Paragangliomas Epidemiology

The Pheochromocytomas and Paragangliomas epidemiology section of the report provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. The total incident cases in the 7MM were nearly 4900 in 2024, projected to increase during the forecast period. These tumors predominantly affect individuals between 40 and 50 years of age. The report highlights geographic variations, age-specific distribution, genetic mutation patterns, and projections for future trends, helping stakeholders understand the scope of Pheochromocytomas and Paragangliomas and plan targeted interventions.

Pheochromocytomas and Paragangliomas Epidemiology Segmentation:

The Pheochromocytomas and Paragangliomas market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Pheochromocytomas and Paragangliomas
• Occurrence or Absence of Mutation in PCPG
• Age-specific Cases of PCPG
• Stage-specific Cases of PCPG

Download the report to understand which factors are driving Pheochromocytomas and Paragangliomas epidemiology trends @ Pheochromocytomas and Paragangliomas Epidemiology Forecast

Recent Development In The Pheochromocytomas and Paragangliomas Treatment Landscape:

• In May 2025, the FDA approved WELIREG (belzutifan) from Merck for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. This represents the first FDA approval of an oral therapy for Pheochromocytomas and Paragangliomas and the third indication for WELIREG in the United States. The approval was based on the Phase 2 LITESPARK-015 trial, which demonstrated an overall response rate of approximately 26% and a median duration of response of about 20 months in 72 patients with advanced Pheochromocytomas and Paragangliomas.
• In June 2025, Perspective Therapeutics commenced recruitment for [212Pb]VMT-α-NET in the third dose escalation cohort of its ongoing Phase 1/2a clinical trial. This novel SSTR2-targeting radioligand therapy utilizes alpha-emitting isotope 212Pb to deliver targeted radiation specifically to cancer cells, representing a promising advancement in targeted alpha therapy for neuroendocrine tumors.
• Results from Phase II LITESPARK‑015 was reported at ESMO 2025, showing meaningful tumor shrinkage and disease control in advanced PPGL, reinforcing the evidence base behind the FDA approval of belzutifan

Pheochromocytomas and Paragangliomas Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Pheochromocytomas and Paragangliomas market or expected to get launched during the study period. The analysis covers Pheochromocytomas and Paragangliomas market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pheochromocytomas and Paragangliomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pheochromocytomas and Paragangliomas Therapies and Key Companies

• WELIREG (belzutifan): Merck
• ONC201: Jazz Pharmaceuticals/Chimerix
• [212Pb]VMT-α-NET: Perspective Therapeutics
• LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate): Novartis, and others.

To know more about Pheochromocytomas and Paragangliomas companies working in the treatment market, visit @ Pheochromocytomas and Paragangliomas Clinical Trials and Therapeutic Assessment

Pheochromocytomas and Paragangliomas Market Drivers

• FDA approval of WELIREG as the first oral systemic therapy for advanced Pheochromocytomas and Paragangliomas in May 2025
• Increasing awareness and improved detection rates through enhanced imaging technologies
• Growing recognition of hereditary Pheochromocytomas and Paragangliomas with expanded genetic testing recommendations
• Development of targeted therapies and radioligand therapies for metastatic disease
• Rising healthcare expenditure and supportive infrastructure in major markets
• Discontinuation of AZEDRA creating demand for alternative treatment options
• Advances in precision medicine approaches based on genetic mutation profiles

Pheochromocytomas and Paragangliomas Market Barriers

• Ultra-rare nature of Pheochromocytomas and Paragangliomas limiting patient populations and clinical trial enrollment
• Complex administrative requirements for radioligand therapies requiring specialized facilities
• High cost of novel targeted therapies potentially limiting patient access
• Limited long-term efficacy data for emerging treatments
• Challenges in predicting malignancy in the absence of detectable metastases
• Withdrawal of AZEDRA highlighting commercial viability challenges in rare diseases
• Geographic disparities in access to specialized diagnostic and treatment centers

Scope of the Pheochromocytomas and Paragangliomas Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Pheochromocytomas and Paragangliomas Companies: Merck, Jazz Pharmaceuticals/Chimerix, Perspective Therapeutics, Novartis, and others
• Key Pheochromocytomas and Paragangliomas Therapies: WELIREG (belzutifan), ONC201, [212Pb]VMT-α-NET, LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), and others
• Pheochromocytomas and Paragangliomas Therapeutic Assessment: Pheochromocytomas and Paragangliomas current marketed and Pheochromocytomas and Paragangliomas emerging therapies
• Pheochromocytomas and Paragangliomas Market Dynamics: Pheochromocytomas and Paragangliomas market drivers and Pheochromocytomas and Paragangliomas market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pheochromocytomas and Paragangliomas Unmet Needs, KOL's views, Analyst's views, Pheochromocytomas and Paragangliomas Market Access and Reimbursement

Discover more about therapies set to grab major Pheochromocytomas and Paragangliomas market share @ Pheochromocytomas and Paragangliomas Treatment Market